Metformin Accord

Metformin, the active ingredient in Metformin Accord, is a Biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control. GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Accord is used in the management of disorders related to impaired glucose regulation. - Type 2 diabetes mellitus: improves glycaemic control and reduces hyperglycaemia. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. - Polycystic ovary syndrome (off‑label): enhances insulin sensitivity and may aid menstrual regularity.

Metformin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: marked elevation of liver enzymes or liver dysfunction. - Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents.

Metformin should be used with careful clinical monitoring and patient education. - Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic status review: monitor liver enzymes before and during therapy. - Lactic acidosis risk: discontinue before radiographic contrast studies or acute heart failure. - Elderly patients: start at lower dose and titrate slowly. - Concomitant medication review: assess for drugs that may affect renal clearance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Acute heart failure: heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Other antidiabetic agents: adjust dosing to prevent hypoglycaemia. - NSAIDs: may reduce renal perfusion and increase metformin levels.